Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS ...

LEXINGTON, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will present a broad set

Related Keywords

Michael Grannan ,Damien Maura ,Varshini Venkatesan ,Todd Carter ,Adam Bero ,Shiron Lee ,Hechen Bao ,Roberto Facendola ,Brett Hoffman ,Matteo Placidi ,Tyler Moyer ,Trista Morrison ,Daniel Cox ,Brooke Shenkin ,Hamza Khalid ,Kishan Shah ,Principal Research ,Nasdaq ,Neurocrine Biosciences Inc ,Sangamo Therapeutics Inc ,American Society Of Gene Cell Therapy ,Senior Research Associate ,Analytical Sciences ,Research Associate ,Voyager Therapeutics Inc ,Exchange Commission ,American Society ,Cell Therapy ,Chief Scientific Officer ,Novel Capsid ,Associate Director ,Senior Scientist ,Matthew Child ,Principal Research Associate ,Downstream Process ,Senior Associate Engineer ,Capsid Discovery ,Tropism Redirection ,Cell Type Specific Expression ,Astrazeneca Rare Disease ,Novartis Pharma ,Neurocrine Biosciences ,Sangamo Therapeutics ,Voyager Therapeutics ,Private Securities Litigation Reform Act ,Annual Report ,